Please login to the form below

budesonide

This page shows the latest budesonide news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca’s mild combination asthma reliever approved in UK

AstraZeneca’s (AZ’s) Symbicort (budesonide/formoterol) Turbohaler 200/6 has been approved in the UK as the first and only combination reliever therapy for adults and adolescents aged 12 years ... Budesonide/formoterol 200/6 reliever therapy helps

Latest news

AstraZeneca and Avillion’s asthma rescue treatment granted FDA approval

The companies’ fixed-dose, pressurised, metered-dose inhaler contains a combination of albuterol, a short-acting beta2-agonist, and budesonide, an anti-inflammatory inhaled corticosteroid. ... In DENALI, Airsupra significantly improved lung function
AZ and Avillion’s asthma rescue treatment recommended by FDA Advisory Committee

PT027 significantly reduced the risk of severe asthma exacerbations. AstraZeneca (AZ) and Avillion’s PT027 (albuterol/budesonide) has been recommended by the US Food and Drug Administration’s (FDA) Pulmonary-Allergy ... Meanwhile, in DENALI, PT027
Phase 3 trial of AstraZeneca and Avillion’s PT027 shows promise for asthma patients

AstraZeneca (AZ) and Avillion have announced positive phase 3 trial results from the MANDALA study, showing that PT027 – albuterol/budesonide – demonstrated a statistically significant decrease in the risk of a severe ... In secondary endpoints,
FDA rejects Takeda’s Eohilia after delays

After more than a year on ‘priority review’, the FDA has said it cannot approve Takeda’s budesonide oral suspension without a further clinical study. ... stuck. Treatment with corticosteroids is common. ‘Orodispersible’ tablets, which dissolve
Oxford University to study antiparasitic drug ivermectin in COVID-19 trial

In April, PRINCIPLE trial researchers found the inhaled asthma medication budesonide can shorten recovery time when administered early to high-risk COVID-19 patients. ... The results showed that the estimated time to self-reported recovery for inhaled

More from news
Approximately 3 fully matching, plus 68 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

410. AstraZeneca (UK). Cilag J&J (US). Asset acquisition. Rhinocort (budesonide) nasal spray for rhinitis, global rights excluding US.
Deal Watch November 2015

So selling off the US rights for Entocort (budesonide), in the non-strategic field of mild to moderate Crohn's disease seems like small beer but the $380m paid by Perrigo ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed
Pharma deals in August 2015

Baxalta aside, it has been a busy year for Shire which in February acquired the company Meritage bringing in a phase III ready oral budesonide solution for eosinophilic oesophagitis [an orphan
Pharma deals in July 2015

Secondly, AZ sold Entocort (budesonide) global rights except the US to Tillotts, for $215m representing a sales multiple of 4. ... 250+. AstraZeneca / Tillotts. Product acquisition. Entocort (budesonide) marketed. 215. Occuleve / Allergan.
Medius Deal Watch table for February 2015

Collaboration - develop and commercialise. 265. Meritage Pharma/ Shire. Phase 3-ready oral budesonide suspension (OBS) - eosinophilic esophagitis (EoE).

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Subscribe to our email news alerts

No results were found

PMHub

Add my company

Grace Communications

We’re an independent healthcare brand communications agency with a host of awards that speak to our success. Combining razor-sharp insights...

Latest intelligence

Clinical Trials Investigator and Patient Engagement Planning: A Customer Story: ...
New Playbook Alert: Virtual Patient Engagement: ...
Millennials: the wellness generation: Looking at the results from a global healthcare research study focusing on the patients of the future...

Email:
Password:

Please login to the form below

budesonide

Subscribe to our email news alerts

Quick links